Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS

Table 2 Association between absence of miR-219 detection and MS

Subject comparisons	OR (95% CI)	p value two-tailed Fisher’s Exact test
Cohort 1
MS (RRMS, PPMS, SPMS) vs. NHI	10.52 (0.5156–214.8)	0.0664
Progressive MS (PPMS, SPMS) vs. NHI	20.78 (0.9238–467.3)	0.0294
SPMS vs. NHI	23.80 (0.8934–634.0)	0.0350
Cohort 2
MS (RRMS, PPMS, SPMS, CIS) vs. controls (NHI, AD, IIH, IND)	2.619 (1.173–5.847)	0.0262
Progressive MS (PPMS, SPMS) vs. controls (NHI, AD, IIH, IND)	3.636 (1.336–9.898)	0.0165
SPMS vs. controls (NHI, AD, IIH, IND)	4.667 (1.291–16.87)	0.0314
CIS vs. controls (NHI, AD, IIH, IND)	1.821 (0.4777–6.945)	0.4594
Cohort 3
MS (RRMS, PPMS, SPMS) vs. controls (NIND, IND)	39.67 (4.104–383.4)	0.0002
RRMS vs. controls (NIND, IND)	26.25 (2.458–280.4)	0.0025
PPMS vs. controls (NIND, IND)	65.00 (2.237–1889)	0.0047
SPMS vs. controls (NIND, IND)	45.50 (3.479–595.1)	0.0010

Significant values are italicized
OR odds ratio, CI confidence interval, CIS clinically isolated syndrome, RRMS relapsing remitting MS, SPMS secondary progressive MS, PPMS primary progressive MS, NHI neurologically healthy individual, AD Alzheimer’s disease, IIH idiopathic intracranial hypertension, NIND non-inflammatory neurological disease, IND inflammatory neurological disease

ISSN: 1742-2094